Investors in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had a good week, as its shares rose 9.7% to close at US$34.54 ...

AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript May 2, 2024 Agios Pharmaceuticals, Inc. isn’t one ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat ...

May 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today reported business ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $81.5 million in its first quarter. The Cambridge, Massachusetts-based company said it ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...